Riskpilot← Back to searchSign inGet full accessVINGMED AS
ASActiveOrg 848236632Solbråveien 13, 1383 AskerWholesale of pharmaceutical and medical goods · NACE 4646Est. 198785 employeeswww.vingmed-as.no
Revenue 2024
NOK 549,6M
+1% vs 2023
EBITDA margin
11.3%
+5% vs 2023
Equity ratio
25.7%
Financial strength
Net profit 2024
NOK 42,8M
-1% vs 2023
| Revenue | NOK 549,6M | +1% |
| EBITDA | NOK 62,2M | +5% |
| Net profit | NOK 42,8M | -1% |
| Total assets | NOK 222,8M | +5% |
| Equity | NOK 57,3M | +6% |
| Employees | 85 | — |
Legal name
VINGMED AS
Org number
848236632
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
14. desember 1987
Share capital
NOK 3 000 000
Employees
85 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Address
Solbråveien 13, 1383 Asker
Website
www.vingmed-as.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 189 029 | 213 221 | 197 184 | 238 018 | 236 648 | 271 272 | 339 730 | 325 059 | 305 558 | 353 961 | 370 744 | 444 096 | 547 116 | 501 124 | 508 954 | 545 004 | 549 584 |
| Staff expenses | −0 | −30 792 | −33 671 | −36 193 | −36 279 | −38 993 | −40 961 | −45 598 | −42 707 | −46 922 | −51 236 | −54 640 | −60 374 | −65 800 | −75 958 | −86 879 | −82 974 | −106 507 |
| EBITDA | 0 | 22 189 | 27 787 | 23 777 | 39 665 | 39 447 | 42 627 | 54 344 | 37 537 | 33 791 | 53 853 | 47 685 | 62 678 | 102 849 | 75 750 | 76 866 | 59 164 | 62 236 |
| Depreciation & amort. | −0 | −2 892 | −1 269 | −1 464 | −1 396 | −1 311 | −1 237 | −1 213 | −1 337 | −1 775 | −2 508 | −3 481 | −4 392 | −5 046 | −6 022 | −6 227 | −5 557 | −5 790 |
| EBIT | 0 | 19 297 | 26 518 | 22 313 | 38 268 | 38 136 | 41 390 | 53 131 | 36 200 | 32 016 | 51 345 | 44 204 | 58 286 | 97 804 | 69 728 | 70 640 | 53 608 | 56 446 |
| Net financials | 0 | 496 | 1 399 | 792 | 212 | 1 245 | −92 | −600 | 487 | 873 | −295 | −469 | 1 712 | −988 | 351 | −1 393 | 1 899 | −1 566 |
| Profit before tax | 0 | 19 793 | 27 917 | 23 105 | 38 481 | 39 381 | 41 298 | 52 531 | 36 686 | 32 888 | 51 050 | 43 734 | 59 998 | 96 815 | 70 079 | 69 247 | 55 506 | 54 880 |
| Tax | −0 | 5 690 | 7 926 | 6 562 | 10 839 | 11 091 | 11 787 | 14 258 | 10 202 | 8 387 | 12 371 | 10 177 | 13 221 | 21 305 | 15 428 | 15 242 | 12 227 | 12 096 |
| Net profit | 0 | 14 102 | 19 991 | 16 542 | 27 642 | 28 290 | 29 511 | 38 274 | 26 485 | 24 501 | 38 679 | 33 557 | 46 778 | 75 510 | 54 651 | 54 005 | 43 280 | 42 783 |
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | 81 301 | 100 811 | 95 182 | 101 684 | 102 749 | 116 799 | 131 437 | 109 095 | 118 696 | 146 020 | 143 772 | 189 507 | 202 034 | 225 890 | 229 908 | 211 589 | 222 844 |
| Equity | — | 18 216 | 18 216 | 18 216 | 18 216 | 18 216 | 18 216 | 18 216 | 18 216 | 19 196 | 20 746 | 20 706 | 20 706 | 50 508 | 56 480 | 57 835 | 54 314 | 57 318 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 61 709 | 81 816 | 76 965 | 83 468 | 84 532 | 98 582 | 113 221 | 90 878 | 99 500 | 125 274 | 123 067 | 168 802 | 151 525 | 169 410 | 172 073 | 157 274 | 165 526 |
| Total debt | 0 | 61 709 | 81 816 | 76 965 | 83 468 | 84 532 | 98 582 | 113 221 | 90 878 | 99 500 | 125 274 | 123 067 | 168 802 | 151 525 | 169 410 | 172 073 | 157 274 | 165 526 |
EBITDA margin
11.3%
This company
15.8%
Market median
-28% vs market
20072024
Equity ratio
25.7%
This company
38.2%
Market median
-33% vs market
20072024
Return on equity
74.6%
This company
18.4%
Market median
+305% vs market
20072024
Net profit margin
7.8%
This company
8.1%
Market median
-4% vs market
20072024
Asset turnover
2.47×
This company
1.12×
Market median
+121% vs market
20072024
Debt / equity
2.89×
This company
0.62×
Market median
-366% vs market
20072024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
- Annual report 2007Filed via Brønnøysundsregistrene · Period 2007-01-01 – 2007-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TK Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2026 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Vingmed Holding As | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Vingmed Holding As
VINGMED AS Board members of VINGMED AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tor Kåre Havnes | Chief Executive Officer | 0 companies |
| Jan Erik Kirkeby | Chairman | 0 companies |
| Ane Lene Hellevik Asheim | Board of Directors | 0 companies |
| Kolbjørn Haarr | Chairman | 0 companies |